Roche’s Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology roche.com
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types roche.com
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer roche.com
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash roche.com
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks roche.com
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer roche.com
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma roche.com
